AHA Coding Clinic® for HCPCS - 2013 Issue 3; For Your Information
Correct reporting of Rituximab and Bevacizumab - dosage vs. units
Rituximab and Bevacizumab are both chemotherapeutic drugs. Rituximab is utilized in the treatment of rheumatoid arthritis, Hodgkin’s lymphoma, and chronic lymphocytic leukemia. Bevacizumab is utilized in the treatment of patients with metastatic colorectal cancer. To accurately report the usage of Rituximab and Benvacizumab, billers and coders must verify the milligrams given and if necessary convert to the proper units, and ensure the quantity administered is consistent with the number of units billed. Key points to remember when billing Medicare for Rituximab: J9310 is defined in the HCPCS manual as: Injection, rituximab, 100 mg. One (1) unit represents 100...
To read the full article, sign in and subscribe to the AHA Coding Clinic® for HCPCS.
Thank you for choosing Find-A-Code, please Sign In to remove ads.